Burning Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>BR</div>
BNR -- USA Stock  

USD 36.65  0.28  0.77%

Today's short post will sum up Burning Rock as your potential position. We will discuss the question of why retail investors should continue to be confident in Burning Rock outlook.
Published over a month ago
View all stories for Burning Rock | View All Stories
Our latest forecast of Burning (NASDAQ:BNR)
Burning Rock is OVERVALUED at 29.25 per share with modest projections ahead. About 19.0% of the company shares are held by institutions such as insurance companies. Insiders ownership of Burning Rock Biotech refers to the amount of Burning Rock Biotech equity owned by Burning officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Burning, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Burning Rock Biotech. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Burning Rock

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Burning Rock's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Burning Rock in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Burning Rock. Your research has to be compared to or analyzed against Burning Rock's peers to derive any actionable benefits. When done correctly, Burning Rock's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Burning Rock Biotech.

How Burning utilizes its cash?

To perform a cash flow analysis of Burning Rock, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Burning Rock is receiving and how much cash it distributes out in a given period. The Burning Rock cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Burning Rock Gross Profit

Burning Rock Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Burning Rock previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Burning Rock Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Breaking down the case for Burning Rock

The latest price spike of Burning Rock Biotech could raise concerns from retail investors as the firm it trading at a share price of 34.30 on very low momentum in volume. The company executives may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.82. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Burning Rock partners.

Are Burning Rock technical ratios showing a bounce back?

Latest Information Ratio is up to 0.05. Price may fall again. Burning Rock Biotech shows above-average downside volatility for the selected time horizon. We advise investors to inspect Burning Rock Biotech further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Burning Rock future alpha.

The Bottom Line

While some other entities within the diagnostics & research industry are still a little expensive, even after the recent corrections, Burning Rock may offer a potential longer-term growth to retail investors. To conclude, as of the 17th of January 2021, our concluding 30 days recommendation on the enterprise is Strong Sell. We believe Burning Rock is currently overvalued with average odds of financial distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Burning Rock Biotech. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com